Symbols

BMY

Bristol-Myers Squibb·NYSE

--(--)

Signals Analysis

Bullish signal 7

Bearish signal 1

High Gross Profit Margin

Significant Net Income Growth

High Cash/net Profit Ratio

Revenue Beats Expectation

EPS Beats Expectation

FDA Approved

Price Hits 52-week Low

RSI Oversold

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About BMY

Bristol-Myers Squibb Company

A global biopharmaceutical company that develops and commercializes innovative medicines for serious diseases

Industry

Pharmaceutical

Established Date

Listing Date

07/05/1929

Exchange

New York Stock Exchange

Full-time Employees

32,500

Fiscal Year Ends

12-31

Website

www.bms.com

Security Type

Common stock

Office address

Route 206 & Province Line Road, Princeton, New Jersey 08543

Business

Biopharmaceuticals and Sales

Introduction

Bristol-Myers Squibb Company was incorporated in Delaware in August 1933. It originated from a business founded in New York in 1887 and was renamed in 1989 due to the merger. As a biopharmaceutical company, Bristol-Myers Squibb focuses on the discovery, development, licensing, production, marketing and sales of innovative drugs to combat serious diseases. The Company's strategic approach combines the resources and scale of large pharmaceutical companies with the flexibility and innovation focus unique to the biotechnology industry. Bristol-Myers Squibb prioritizes transformative medicines in the fields of oncology, hematology, immunology, cardiovascular and neuroscience, aiming to provide long-term value and competitive advantage. As a global research pharmaceutical company, Bristol-Myers Squibb sells its products worldwide, serves a variety of entities including wholesalers, distributors and specialty pharmacy, and maintains important production operations in several countries.

Company Financials

EPS

BMY has released its 2025 Q4 earnings. EPS was reported at 1.26, versus the expected 1.19, beating expectations. The chart below visualizes how BMY has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

BMY has released its 2025 Q4 earnings report, with revenue of 12.50B, reflecting a YoY change of 1.30%, and net profit of 1.08B, showing a YoY change of 1327.63%. The Sankey diagram below clearly presents BMY's revenue sources and cost distribution.